Quetiapine for the Treatment of Delirium

Stefanie B. Hawkins, PharmD1, Mason Bucklin, PharmD2, Andrew J. Muzyk, PharmD3,4

1Emergency Medicine, University of Kansas Hospital, Kansas City, Kansas; 2Department of Pharmacy, University of Rochester Medical Center, Rochester, New York; 3Department of Pharmacy Practice, Campbell University School of Pharmacy and Health Sciences, Buies Creek, North Carolina, and Department of Psychiatry and Behavioral Sciences, Duke University, Durham, North Carolina.

BACKGROUND: Delirium is associated with high rates of morbidity and mortality in hospitalized medically ill patients. Haloperidol has historically been the agent of choice for the treatment of delirium, but recent studies have explored the efficacy of second-generation antipsychotics such as quetiapine. The unique pharmacology of quetiapine may allow it to treat delirium and provide sedation without causing significant extrapyramidal side effects.

PURPOSE: To evaluate the efficacy of quetiapine for the treatment of delirium.

DATA SOURCES: A search was conducted in MEDLINE and Embase (January 1960–December 2012) using keywords “quetiapine,” “second-generation antipsychotic,” “atypical antipsychotic,” “delirium,” and “agitation.”

STUDY SELECTION AND DATA EXTRACTION: The search was limited to English-language articles and trials with treatment of delirium as the primary end point. Eight trials met this inclusion criterion.

DATA SYNTHESIS: Two randomized controlled trials, 5 open-label studies, and 1 retrospective cohort study evaluating quetiapine for the treatment of delirium were reviewed. One randomized controlled trial showed no differences in total mean delirium scores, but found the rate of delirium improvement was significantly shorter with quetiapine. The second randomized controlled trial showed the time to first resolution of delirium was shorter with quetiapine compared to placebo. Results of the open-label and retrospective cohort trials have also shown significant resolution of delirium from baseline and equal efficacy with quetiapine compared to amisulpride and haloperidol.

CONCLUSIONS: Quetiapine appears to be an effective and safe agent for the treatment of delirium in both general medicine and intensive care unit patients. The trials summarized suggest that quetiapine resolves symptoms of delirium more quickly than placebo and has equal efficacy compared to haloperidol and the atypical antipsychotic amisulpride. Further study is needed. Journal of Hospital Medicine 2013;8:215–220. © 2013 Society of Hospital Medicine

Delirium is an acute fluctuation in mental status that includes symptoms of inattention, disorganized thinking, and altered level of consciousness occurring over a short time period.1 Prevalence of delirium ranges from 10% to 30% in the hospitalized medically ill and ranges from 40% to 60% in intensive care unit (ICU) patients who are not receiving mechanical ventilation.2,3 Patients experience delirium more often if they are of older age; have dementia, cancer, or acquired immune deficiency syndrome; have undergone surgery; are terminally ill; or have received multiple psychoactive medications, particularly benzodiazepines or opioids.3–7 Delirium is associated with high rates of morbidity and mortality,8 with patients more likely to develop complications such as pneumonia, decubitus ulcers, and long-term cognitive deficits.9–12 These complications, in turn, lead to longer hospital stays and increased costs of care.13,14 Currently, there are no antipsychotics approved by the US Food and Drug Administration for the treatment of delirium.

Both the 2002 American Society of Critical Care Medicine12 and the 2004 American Psychiatric Association guidelines15 on delirium recommend haloperidol as the antipsychotic of choice due to its potent tranquilizing effect, lack of active metabolites, and limited anticholinergic and sedating side effects. However, when given intravenously or at high cumulative doses (generally >35 mg/day), haloperidol has been shown to cause QT interval prolongation potentially leading to torsades de pointes and sudden cardiac death.13 Recent research in delirium treatment has focused on the second-generation antipsychotics, and these studies have reported positive findings,16–29 although no significant differences have been found compared to haloperidol.16–18,22–24 Systematic reviews have also failed to show a significant difference in efficacy or safety between second-generation and first-generation antipsychotics and unfortunately report a number of limitations including poor study designs, small sample sizes, lack of a placebo control group, exclusion of ICU patients, and weak primary outcomes.8,30–32 Attempting to correct for a number of these limitations, recent research with quetiapine has reported promising results in 2 controlled studies.19,20

*Address for correspondence and reprint requests: Andrew J. Muzyk, PharmD, P.O. Box 3089–Pharmacy, Durham, NC 27710; Telephone: 919-681-3438; Fax: 919-681-2741; E-mail: andrew.muzyk@duke.edu

Additional Supporting Information may be found in the online version of this article.

Received: October 24, 2012; Revised: January 8, 2013; Accepted: January 15, 2013
2013 Society of Hospital Medicine DOI 10.1002/jhm.2019 Published online in Wiley Online Library (Wileyonlinelibrary.com).
Quetiapine is a second-generation antipsychotic with a very low affinity for dopamine receptors and a very high affinity for serotonin receptors. Additionally, quetiapine has a high affinity for histamine and α1-adrenergic receptors, but a very low affinity for M1 muscarinic receptors. This mechanism of action may allow quetiapine to effectively treat delirium and provide sedation without causing significant extrapyramidal side effects associated with potent dopamine receptor antagonism or precipitating delirium through muscarinic receptor antagonism. Quetiapine has a rapid absorption and a short half-life (3–6 hours), giving it a quick onset of action and a fast elimination from the body. Unlike haloperidol, it is only available in oral dosage forms, but can be crushed to administer via enteral tube. Common reported adverse effects include somnolence, hypotension, and dizziness. Although quetiapine has been shown to prolong QTc, Harrigan et al. reported a mean increase in QTc from baseline of 5.7 msec; there was no significant effect on this change in the presence of a metabolic inhibitor, ketoconazole. The mean change in QTc from baseline with quetiapine was lower than the change reported with oral haloperidol, 5.7 msec compared to 7.1 msec, respectively. No statistical comparison was performed between these 2 drugs on this measure. Quetiapine does carry a black box warning for increased mortality in elderly patients with dementia-related psychosis. However, this risk has also been found with first-generation antipsychotics. A recent study found this risk of sudden cardiac death extended to adult users of both first-and second-generation antipsychotics. In contrast, Elie et al. found no increased risk of mortality in elderly patients with delirium receiving antipsychotics—over 90% were prescribed either haloperidol or risperidone—in their nested case-controlled study. Quetiapine has demonstrated some benefit with limited side effects in studies utilizing antipsychotics for the treatment of delirium. The purpose of this review was to evaluate the role of quetiapine for the treatment of delirium.

**LITERATURE REVIEW**

We performed an English-language literature search of MEDLINE and Embase databases to identify journal articles published between January 1960 and December 2012. Keywords included “quetiapine,” “second-generation antipsychotic,” “atypical antipsychotic,” “delirium,” and “agitation.” The search was limited to English-language articles and adult subjects (>18 years). Based on our review of abstracts, we included both controlled and noncontrolled trials as long as treatment of delirium was the primary focus. We eliminated case reports, foreign language articles, and poster presentations. We identified 8 trials that included 2 double-blind, randomized, placebo-controlled trials, which are described in the text below. Six other trials, 5 open-label and 1 retrospective cohort, are described in Table 1.

**Randomized Controlled Trials**

Tahir et al. published a double-blind, randomized, placebo-controlled trial examining the efficacy and tolerability of quetiapine in the treatment of delirium. Inclusion criteria were a Diagnostic and Statistical Manual of Mental Disorders-IV diagnosis of delirium and a Delirium Rating Scale Revised 98 (DRS-R-98) total score of at least 15, indicating the presence of delirium. Subjects were excluded for major preexisting cognitive deficits, alcohol withdrawal, preexisting psychosis, substance dependence, inability to comply with the constraints of the trial, and concurrent medications that interact with quetiapine.

Forty-two general medicine subjects were enrolled and randomized in the study with no difference in baseline characteristics. Patients received either placebo or quetiapine 25 mg once daily. Doses were titrated by 25 mg daily to a maximum daily dose of 175 mg in divided doses. The primary end point was DRS-R-98 total mean score assessed on days 1, 2, 3, 4, 7, and 10, with follow-up assessment on day 30. Secondary outcome measures were Mini-Mental State Examination (MMSE), the Brief Psychiatric Rating Scale, and the Clinical Global Improvement Scale. Tolerability was assessed using the Abnormal Involuntary Movements Scale and by clinical examination.

No differences in total mean DRS-R-98 score at individual time points reached statistical significance, but these scores improved more quickly in the quetiapine group than placebo. The secondary outcome of rate of delirium improvement on severity score did reach statistical significance; differences on mean severity scores were 0.827 ± 0.37 (P = 0.026), suggesting that severity scores improved 82% more quickly than placebo. There were no significant differences between groups for any of the other secondary outcomes. Seven patients died within 30 days of entering the study (4 in the quetiapine group and 3 in the placebo group) due to serious medical conditions and not due to study medication as determined through clinical review. One patient withdrew from quetiapine due to sedation. Results of this study are limited by a small sample size, as it was underpowered to detect a statistically significant difference in the primary outcome. Other limitations include subjects who were older, with mean age of 84 years, which may have prevented titration of quetiapine, and subjects with minor cognitive deficits were included, which may have reduced the impact of treatment on the study outcomes. Additionally, strict criteria for exclusion kept those patients most likely to develop delirium from being included, limiting the studies external validity. Finally, the use of DRS-R-98 mean total and
### TABLE 1. Descriptions of One Retrospective Cohort \(^{24}\) and Five Open-Label \(^{25-29}\) Trials.

<table>
<thead>
<tr>
<th>Study</th>
<th>Study Design</th>
<th>No. of Patients Included in Analyses</th>
<th>Patient Type</th>
<th>Treatment</th>
<th>Baseline Delirium Scores</th>
<th>Quetiapine Dose (mg/day) (Mean ± SD)</th>
<th>Efficacy Measures</th>
<th>Results</th>
<th>Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schwartz et al. (2000)</td>
<td>RC</td>
<td>22</td>
<td>General hospital</td>
<td>Quetiapine or haloperidol flexible dose</td>
<td>DRS score: 20.9 Q; 18.5 H</td>
<td>211.4 ± 3.4 H; 218.5 ± 3.2 H</td>
<td>&gt;50% improvement in DRS scores</td>
<td>10/11 in each treatment group had &gt;50% improvement in DRS scores</td>
<td>EPS 2/11 H and 0/11 Q; mild-to-moderate sedation 0/11 H and 0/11 Q</td>
</tr>
<tr>
<td>Pae et al. (2004)</td>
<td>OL</td>
<td>22</td>
<td>Neurosurgery and orthopedic surgery and oncology</td>
<td>Flexible dose quetiapine</td>
<td>DRS-R-98 score: 21.8 ± 3.2 and CGI-s: 4.9 ± 0.8</td>
<td>127.1 ± 72.2</td>
<td>&gt;50% reduction in DRS-R-98 and CGI-s scores</td>
<td>Reduction in DRS-R-98 and CGI-s score reduction</td>
<td>19/17 (88.2%) had &gt;50% reduction in DRS score, all DRS and CGI-s scores on days 1–7 of the 7-day treatment course were significantly lower than baseline scores</td>
</tr>
<tr>
<td>Maneeton et al. (2007)</td>
<td>OL</td>
<td>17</td>
<td>General hospital</td>
<td>Quetiapine 25–100 mg/day in 1 or 2 divided doses</td>
<td>DRS: 24.5 ± 3.2 and CGI-s: 4.9 ± 0.9</td>
<td>45.7 ± 28.7</td>
<td>&gt;50% reduction in DRS scores</td>
<td>Reduction in DRS, MMSE, CGI-s, or CDT scores</td>
<td>15/17 (88.2%) had &gt;50% reduction in DRS score; all DRS and CGI-s scores on days 1–7 of the 7-day treatment course were significantly lower than baseline scores</td>
</tr>
<tr>
<td>Kim et al. (2003)</td>
<td>OL</td>
<td>12 (all male and age ≥ 64 years)</td>
<td>General hospital</td>
<td>Quetiapine 25 mg BID and increased by 25 mg every 2 days until patient maximally stabilized</td>
<td>DRS: 18.25 ± 6.05; MMSE: 14.50 ± 5.90; CGI-s: 3.00 ± 0.43; CDT: 3.25 ± 2.77</td>
<td>93.75 ± 23.31</td>
<td>Reduction in DRS, MMSE, CGI-s, or CDT scores</td>
<td>All scores were statistically significantly improved from baseline; DRS at end of study: 0.63 ± 1.21 (P = 0.03)</td>
<td>No statistically significant change from baseline in EPS; no excessive daytime sedation, anticholinergic effects, vital sign, or lab parameter changes</td>
</tr>
<tr>
<td>Sasaki et al. (2003)</td>
<td>OL</td>
<td>12</td>
<td>General hospital</td>
<td>Quetiapine started at 25 or 50 mg/day and titrated to maximal clinical effect</td>
<td>DRS-J: 18.1 ± 4.2</td>
<td>44.9 ± 31.0</td>
<td>Remission was DRS-J score &lt; 12 (cut-off for delirium) and resolution of delirium symptoms</td>
<td>Remission occurred in all patients; mean DRS-J score was reduced to 9.3 ± 1.6 after remission</td>
<td>No statistically significant change from baseline in EPS; no excessive daytime sedation, anticholinergic effects, vital sign, or lab parameter changes</td>
</tr>
<tr>
<td>Lee et al. (2005)</td>
<td>OL</td>
<td>31</td>
<td>Neurosurgery and orthopedic surgery, internal medicine, neurology and rehabilitation medicine</td>
<td>Flexible dose quetiapine or amisulpride</td>
<td>DRS-R-98: 10.1 ± 4.1 Q and 10.5 ± 4.1 A</td>
<td>113 ± 85.5 Q; 136.4 ± 97.5 A</td>
<td>Reduction in DRS-R-98 score</td>
<td>DRS-R-98 scores significantly reduced from baseline in both groups with 3.5 ± 2.6 G (P = 0.001) and 3.5 ± 1.4 A (P = 0.000), no difference between groups (P &gt; 0.942), 12 (60%) Q and 13 (61.5%) A had &gt;50% reduction in DRS-R-98 score</td>
<td>No statistically significant change from baseline in EPS; no excessive daytime sedation, anticholinergic effects, vital sign, or lab parameter changes</td>
</tr>
</tbody>
</table>

**NOTE:** Abbreviations: A: amisulpride; BID, twice a day; CDT, Clock Drawing Test; CGI-s, Clinical Global Impression Scale-Severity; DRS, Delirium Rating Scale; DRS-R-98, Delirium Rating Scale-Japanese version; DRS-R-98, Delirium Rating Scale-Revised Severity 98; EPS, extrapyramidal symptoms; H, haloperidol; IV, Intravenous; MMSE, Mini-Mental State Exam; NR, not reported; OL, open label; Q, quetiapine; RC, retrospective cohort; SD, standard deviation.
severity scores is subject to error as outliers in the mean could potentially skew the results.

Devlin et al. investigated the efficacy and safety of quetiapine for ICU delirium in critically ill patients in a double-blind, randomized, placebo-controlled trial. Inclusion criteria were an Intensive Care Delirium Screening Checklist Score (ICDSC) >4, which indicates the presence of delirium, an order for as-needed haloperidol, and tolerating enteral nutrition. Patients were excluded if they had a complicating neurologic condition, current treatment with dexmedetomidine or with medications that interact with quetiapine, baseline QTc interval >500, pregnancy, or poor prognosis. Thirty-six critically ill subjects were randomized with no significant differences in baseline characteristics including exposure to fentanyl, haloperidol, and benzodiazepines, and in particular, midazolam. If the subject received at least 1 dose of as-needed haloperidol in the previous 24 hours, then either placebo or quetiapine was given. Quetiapine was initiated at 50 mg every 12 hours and titrated up by 50 mg every 12 hours to a maximum dose of 200 mg every 12 hours. Patients could receive intravenous haloperidol, 1 to 10 mg up to every 2 hours as needed. The primary outcome was time to first resolution of delirium defined as time from administration of the first dose of study drug until an ICDSC <3 was first detected, indicating an absence of delirium. Secondary outcomes were total hours in delirium, total hours spent “deeply sedated” (Sedation-Agitation Scale [SAS] <2) or agitated (SAS >5), episodes of subject-initiated device removal, use of haloperidol therapy including total dose in milligrams, number of doses and number of days of therapy, the use of sedatives (converted to midazolam equivalents) and analgesics, duration of study-drug administration, average daily and maximum study-drug dose, length of mechanical ventilation, duration of both ICU and hospital stay, hospital mortality, and disposition of subjects after hospital discharge. Safety measures were total number of adverse and serious adverse events, episodes of somnolence, incidence of extrapyramidal symptoms, and episodes of QTc interval prolongation.

The time to first resolution of delirium was shorter with quetiapine compared to placebo (median [interquartile range]: 1.0 [0.5–3.0] vs 4.5 days [2.0–7.0]; P = 0.001). Resolution of delirium occurred at least once in all quetiapine patients and in 78% of placebo patients (P = 0.05). Statistical significance with quetiapine compared to placebo. However, quetiapine subjects had a longer time to resolution of agitation (3 vs 1 day, P = 0.04) and hyperactivity (5 vs 1 day, P < 0.04). The authors attribute these findings to the higher use of as-needed haloperidol in the placebo group (1.9 vs 4.3 mg per day, P = 0.26). These results may also be due to a limitation in the study design, which self-selected for agitation delirium by requiring the use of as-needed haloperidol as inclusion criteria, as symptoms of agitation would be more likely to receive as-needed haloperidol doses. In addition, subjects were allowed to receive 1 to 10 mg of haloperidol up to every 2 hours as needed, but there is no discussion of controlling total daily haloperidol dose in each group in the study. Although 1.9 versus 4.3 mg per day is neither statistically nor likely clinically significant, haloperidol is a treatment for delirium, so the study design would be stronger if quetiapine could be directly compared to an equivalent daily dose of haloperidol or if both groups received the same daily dose of haloperidol. Study results are also limited by the nature of a post hoc analysis, missing documentation for individual delirium symptoms, symptoms of delirium not being well characterized and subjective, and delay in enrollment of subjects.

Noncontrolled Trials

Six additional trials are included in the table of this review including 5 open label trials and 1 retrospective cohort study. Schwartz and Masand24 and Lee et al.29 compared the efficacy of quetiapine to
haloperidol and amisulpride, a second-generation antipsychotic unavailable in the United States, respectively. In a retrospective cohort of 22 general hospital patients, Schwartz and Masand found quetiapine (average dose, 211.4 mg/day) was as efficacious as haloperidol (average dose, 3.4 mg/day) in improving delirium rating scale (DRS) scores by more than 50% in 10/11 subjects in each group. Lee et al. also found quetiapine (average dose, 113.0 mg/day) to be equally efficacious to amisulpride (156.4 mg/day) in statistically significantly improving DRS-R-98 scores in 31 neurosurgery, orthopedic surgery, internal medicine, neurology, and rehabilitation medicine patients. Four open-label studies tested the efficacy of flexible doses of quetiapine in a total of 63 general hospital, neurosurgery, orthopedic surgery, and oncology patients.25–28 Pae et al.,25 Maneeton et al.,26 and Kim et al.27 found that quetiapine statistically significantly reduced DRS-R-98, Clinical Global Impression Scale-Severity, DRS, MMSE, and Clock Drawing Test scores from baseline. Sasaki et al.28 found all 12 general hospital patients in their study reached remission with an average daily quetiapine dose of 44.9 mg/day. Although these studies have a limited level of evidence due to their small sample sizes, study designs, and heterogeneous subjects, they do still suggest that quetiapine may effectively treat delirium in various patient populations.

DISCUSSION

Although the role of quetiapine for the treatment of delirium continues to develop, the studies evaluated here suggest that quetiapine may be effective and safe for this usage. Resolution of delirium from baseline was shown in all studies. Quetiapine resolved symptoms of delirium more quickly than placebo and had equal efficacy to other antipsychotics, haloperidol and amisulpride. Quetiapine may be most useful for patients with symptom fluctuation as opposed to agitation and hyperactivity or in those patients who may not tolerate haloperidol well. Both randomized control and open-label trials found a low incidence of adverse effects with quetiapine. There were fewer incidences of QT prolongation and extrapyramidal symptoms, but higher a rate of somnolence with quetiapine compared to other antipsychotics in these trials. However, none of these differences in adverse effects reached statistical significance.

Drawing definitive conclusions about the efficacy of quetiapine in the treatment of delirium is difficult due to multiple study limitations. First, the body of literature is small, with only 2 randomized controlled trials, both of which had limitations. Tahir et al.19 was underpowered and found no statistically significant difference in the primary end point, DRS-R-98 total mean score. Devlin et al.20 tested the primary end point of time to first resolution of delirium, which may be interpreted as a less rigorous measure because there is no standard definition for delirium resolution. Furthermore, both randomized controlled and observational trials tested the efficacy of quetiapine using different tests, making comparison between these trials difficult. All studies included in this review were carried out in small patient populations, with the largest trial having 42 subjects, and had highly restrictive exclusion criteria limiting the generalizability of the study population to the general hospital population. Although most of the patients included in these studies are general hospital populations, Devlin et al. was performed in critically ill patients, which creates the additional limitation of having heterogeneous study populations. Last, superiority of any 1 antipsychotic is not possible given that none of these studies have done a head-to-head comparison of quetiapine with another atypical antipsychotic.

Given the comparable efficacy and safety of antipsychotics, cost is a relevant factor in treatment decisions. Haloperidol is supplied as either a suspension for injection or a tablet. One vial of 5 mg/mL haloperidol is $8.32. Haloperidol 5 mg tablets are approximately $0.29 each, whereas 25 mg tablets of quetiapine are approximately $3.53 each. However, these prices are for consumers and will vary depending on institutional contracts.42

CONCLUSION

Quetiapine appears to be an effective and safe agent for the treatment of delirium in both general medicine and ICU patients. Superiority of quetiapine over other antipsychotics for hospital-associated delirium has not been shown due to limitations in quality and quantity of data. Large, randomized, double-blind, active control studies with longer study durations are needed to elucidate the efficacy and niche of quetiapine in the treatment of delirium.

Disclosure: Nothing to report.

References


